CGRP Antibodies Improve Sleep Quality in Migraine Patients Better Than Traditional Oral Preventives | Research

The takeaway

Anti-CGRP monoclonal antibodies significantly improved sleep quality (PSQI scores) in migraine patients, outperforming traditional oral prophylactic therapies in a 214-patient Italian multicenter study.

PSQI improvement 1.49 points with CGRP mAbs
Anti-CGRP antibodies produced the most significant sleep quality improvement among all migraine preventive therapies

What the researchers found

Anti-CGRP mAbs produced the greatest improvement in PSQI sleep scores (mean difference 1.49, p=0.010) compared to oral prophylactic therapies in a 3-month multicenter study of 214 migraine patients.

Why it matters

Sleep disruption is both a trigger and consequence of migraine. Treatments that improve both migraine and sleep could break this cycle more effectively than those targeting only headache frequency.

The numbers in context

Multicenter Italian study; compared oral prophylactics vs. anti-CGRP mAbs on sleep quality (specific metrics not detailed in abstract excerpt).

How the study worked

Prospective multicenter study at 3 Italian headache centers. 214 migraine patients assigned to first-line oral drugs or anti-CGRP mAbs. PSQI and MIDAS scales administered at baseline and 3 months.

Who was studied

Italian migraine patients on preventive treatments (oral drugs or CGRP mAbs)

What this study cannot tell us

Non-randomized assignment to treatment groups. 3-month follow-up — long-term sleep effects unknown. PSQI is subjective. No objective sleep measures (polysomnography, actigraphy). Open-label design may introduce placebo effects.

How to read the evidence

Moderate evidence — prospective multicenter study with validated outcome measures, but non-randomized treatment assignment and subjective sleep assessment.

When this study was published

Published in 2024. Adds sleep quality data to the growing evidence base for CGRP antibody benefits.

The bigger picture

The sleep-migraine relationship is bidirectional and often undertreated. CGRP antibodies' dual benefit on both headache and sleep adds another dimension to their value proposition beyond simple headache day reduction.

Questions still open

Do CGRP antibodies improve sleep through direct CGRP modulation in sleep-regulating brain regions, or indirectly via migraine reduction?
Would objective sleep measures (polysomnography) confirm the PSQI improvements?
Does improved sleep quality with CGRP mAbs predict better long-term migraine outcomes?

Common questions

Can CGRP migraine drugs help with sleep problems?

Yes — this study of 214 patients found that anti-CGRP antibodies (drugs like Aimovig, Emgality, Ajovy) improved sleep quality more than traditional migraine pills. Since poor sleep is both a cause and consequence of migraines, this dual benefit could help break the sleep-migraine cycle.

Why does treating migraines improve sleep?

Migraine and sleep share brain pathways involving CGRP and other neuropeptides. By blocking CGRP, these antibodies may directly improve sleep regulation while also reducing the nighttime pain and anxiety that disrupt sleep in migraine patients.

Read the original research

Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: An Italian multicenter study.

Sleep medicine, 117, 87-94

View on PubMed ↗Publisher’s paper ↗

Citation

Viticchi, Giovanna; Di Stefano, Vincenzo; Altamura, Claudia; Falsetti, Lorenzo; Torrente, Angelo; Brunelli, Nicoletta; Salvemini, Sergio; Alonge, Paolo; Bartolini, Marco; Di Felice, Chiara; Adragna, Maria Stella; Moroncini, Gianluca; Vernieri, Fabrizio; Brighina, Filippo; Silvestrini, Mauro. (2024). Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: An Italian multicenter study.. Sleep medicine, 117, 87-94. https://doi.org/10.1016/j.sleep.2024.03.026